Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma

Blood

Volumn 110, Issue 13, 2007, Pages 4455-4463

  Cerhan, James R ^a   Ansell, Stephen M ^a   Fredericksen, Zachary S ^a   Kay, Neil E ^a   Liebow, Mark ^a   Call, Timothy G ^a   Dogan, Ahmet ^a   Cunningham, Julie M ^a   Wang, Alice H ^a   Liu Mares, Wen ^a   Macon, William R ^a   Jelinek, Diane ^b   Witzig, Thomas E ^a   Habermann, Thomas M ^a   Slager, Susan L ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; B3GNT3 GENE; BAT2 GENE; BLOOD CLOTTING; CONTROLLED STUDY; CREB1 GENE; DUSP2 GENE; FEMALE; FGG GENE; GENE; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENETICS; INFLAMMATION; ITGB3 GENE; LEUKEMOGENESIS; LSP1 GENE; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; MAP3K5 GENE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RIPK3 GENE; SELPLG GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TLR6 GENE; TRAF1 GENE; UNC84B GENE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; RISK; STATISTICAL MODEL; TUMOR GENE;

CASE-CONTROL STUDIES; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; IMMUNITY; INFLAMMATION; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; VARIATION (GENETICS);

EID: 36148966588     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-088682     Document Type: Article

References (78)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120:1-39.
4. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600-1608.
5. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479-3488.
6. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science. 1997;278:1580-1581.
7. Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol. 1999;107:388-391.
8. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38.
9. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-hodgkin lymphoma. Cancer Res. 2006;66:9771-9780.
10. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004;103:3529-3534.
11. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107:4101-4108.
12. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol. 2006;134:180-183.
13. Jaffe ES, Harris N, Stein H, Vardiman J. World Health Organization classification of tumours pathology and genetics, tumours of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
14. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res. 2005;15:269-275.
15. Moorhead M, Hardenbol P, Siddiqui F, et al. Optimal genotype determination in highly multiplexed SNP data. Eur J Hum Genet. 2006;14:207-215.
16. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425-434.
17. Chapman JM, Cooper JD, Todd JA, Clayton DG. Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power. Hum Hered. 2003;56:18-31.
18. Taylor J, Tibshirani R. A tail strength measure for assessing the overall univariate significance in a dataset. Biostatistics. 2006;7:167-181.
19. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945-959.
20. Shiraishi N, Natsume A, Togayachi A, et al. Identification and characterization of three novel beta-1,3-N-acetylglucosaminyltransferases structurally related to the beta-1,3-galactosyltransferase family. J Biol Chem. 2001;276:3498-3507.
21. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309-5318.
22. Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol. 2005;83:429-439.
23. Hashimoto M, Nakamura N, Obayashi H, et al. Genetic contribution of the BAT2 gene microsatellite polymorphism to the age-at-onset of insulin-dependent diabetes mellitus. Hum Genet. 1999;105:197-199.
24. Singal DP, Li J, Zhu Y. HLA class III region and susceptibility to rheumatoid arthritis. Clin Exp Rheumatol. 2000;18:485-491.
25. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 2004;50:1077-1082.
26. Kinjo K, Sandoval S, Sakamoto KM, Shankar DB. The role of CREB as a proto-oncogene in hematopoiesis. Cell Cycle. 2005;4:1134-1135.
27. Arcinas M, Heckman CA, Mehew JW, Boxer LM. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res. 2001;61:5202-5206.
28. Ji L, Mochon E, Arcinas M, Boxer LM. CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas. J Biol Chem. 1996;271:22687-22691.
29. Conkright MD, Montminy M. CREB: the unindicted cancer co-conspirator. Trends Cell Biol. 2005;15:457-459.
30. Shankar DB, Cheng JC, Kinjo K, et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell. 2005;7:351-362.
31. Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol. 2006;177:7497-7504.
32. Rohan PJ, Davis P, Moskaluk CA, et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science. 1993;259:1763-1766.
33. Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature. 1994;367:651-654.
34. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 2003;422:527-531.
35. Jeffrey KL, Brummer T, Rolph MS, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006;7:274-283.
36. Boccaccio C, Medico E. Cancer and blood coagulation. Cell Mol Life Sci. 2006;63:1024-1027.
37. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558-1566.
38. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood. 2005;106:4176-4183.
39. Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst. 2003;95:1150-1157.
40. May W, Korenberg JR, Chen XN, et al. Human lymphocyte-specific pp52 gene is a member of a highly conserved dispersed family. Genomics. 1993;15:515-520.
41. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275:90-94.
42. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
43. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55-72.
44. Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. RIP3, a novel apoptosis-inducing kinase. J Biol Chem. 1999;274:16871-16875.
45. Yu PW, Huang BC, Shen M, et al. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr Biol. 1999;9:539-542.
46. Yang Y, Hu W, Feng S, Ma J, Wu M. RIP3 beta and RIP3 gamma, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis. Biochem Biophys Res Commun. 2005;332:181-187.
47. Ma L, Raycroft L, Asa D, Anderson DC, Geng JG. A sialoglycoprotein from human leukocytes functions as a ligand for P-selectin. J Biol Chem. 1994;269:27739-27746.
48. Hidari KI, Weyrich AS, Zimmerman GA, McEver RP. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. J Biol Chem. 1997;272:28750-28756.
49. Hoffjan S, Stemmler S, Parwez Q, et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet. 2005;6:34.
50. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2006;16:32-37.
51. Puthothu B, Heinzmann A. Is toll-like receptor 6 or toll-like receptor 10 involved in asthma genetics - or both? Allergy. 2006;61:649-650.
52. Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000;165:5084-5096.
53. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002;100:3749-3756.
54. Siemienski K, Peters N, Scheurich P, Wajant H. Organization of the human tumour necrosis factor receptor-associated factor 1 (TRAF1) gene and mapping to chromosome 9q33-34. Gene. 1997;195:35-39.
55. Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF1 is a negative regulator of TNF signaling: enhanced TNF signaling in TRAF1-deficient mice. Immunity. 2001;15:647-657.
56. Bryce PJ, Oyoshi MK, Kawamoto S, Oettgen HC, Tsitsikov EN. TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45. Int Immunol. 2006;18:101-111.
57. Hodzic DM, Yeater DB, Bengtsson L, Otto H, Stahl PD. Sun2 is a novel mammalian inner nuclear membrane protein. J Biol Chem. 2004;279:25805-25812.
58. Wang Q, Du X, Cai Z, Greene MI. Characterization of the structures involved in localization of the SUN proteins to the nuclear envelope and the centrosome. DNA Cell Biol. 2006;25:554-562.
59. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis. 2007;28:704-712.
60. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
61. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002;100:3037-3040.
62. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-190.
63. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006;7:615-624.
64. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases: regulating the immune response. Nat Rev Immunol. 2007;7:202-212.
65. Jornot L, Petersen H, Junod AF. Modulation of the DNA binding activity of transcription factors CREB, NFkappaB and HSF by H2O2 and TNF alpha: differences between in vivo and in vitro effects. FEBS Lett. 1997;416:381-386.
66. Gustin JA, Pincheira R, Mayo LD, et al. Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. Am J Physiol Cell Physiol. 2004;286:C547-555.
67. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol Lett. 2006;104:89-93.
68. Blanks JE, Moll T, Eytner R, Vestweber D. Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1. Eur J Immunol. 1998;28:433-443.
69. St-Pierre Y. Organizing a tete-a-tete between cell adhesion molecules and extracellular proteases: a risky business that could lead to the survival of tumor cells. Front Biosci. 2005;10:1040-1049.
70. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001;12:43-50.
71. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2001;2:608-613.
72. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia. 2006;20:1331-1340.
73. Bennett JS, Catella-Lawson F, Rut AR, et al. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood. 2001;97:3093-3099.
74. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19:1142-1147.
75. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol. 2000;110:965-967.
76. Vijayan KV, Liu Y, Dong JF, Bray PF. Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. J Biol Chem. 2003;278:3860-3867.
77. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
78. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239-1248.